Pharmacare plan relying on generic drugs could prompt reaction from big pharma: memo

OTTAWA — Brand-name drug companies could put off introducing new medicine in Canada and scale back research here if the country makes a major shift to cheaper generic alternatives under a national pharmacare plan, according to an internal federal analysis.The concerns were included last year in a briefing document for federal Finance Minister Bill Morneau that explored the feasibility and costs of a pharmacare program.READ MORE: No pharmacare in federal budget, but funding for a national drug agencyPharmacare is shaping up as a key campaign issue in the October election, particularly for the Liberals.The Finance Department’s analysis was created a few days before Morneau’s 2018 budget officially launched an advisory group on Canada-wide pharmacare, which the Liberals say will cut costs and improve Canadians’ access to prescription drugs.WATCH: Here are the goodies found in the 2019 federal budget

Leave a comment